Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Liver Function Tests Clear all
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Phase 1Phase 2 Interventional

Liver Transplantation With Tregs at MGH

NCT03577431
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg-CSB, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

NCT02533180
View directory record Official record
Conditions
Liver Transplant, Liver Transplantation
Interventions
Immunosuppression withdrawal
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 22, 2026, 8:05 AM EDT
Not listed No phase listed Observational

ALT Routinely Recorded Remotely: A Comparator Study of Liver Function Tests Using the Tasso+ to Venipuncture.

NCT05259618
View directory record Official record
Conditions
Elevated Alanine Transaminase (ALT)
Interventions
Tasso+ SST
Other
Lead sponsor
Tasso Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Aurora, Colorado • New York, New York • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer

NCT01522937
View directory record Official record
Conditions
Liver Cancer, Hepatocellular Cancer
Interventions
individualized Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 22, 2026, 8:05 AM EDT
Recruiting No phase listed Observational

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

NCT06683092
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 22, 2026, 8:05 AM EDT
Active, not recruiting No phase listed Observational

Alpha-1 Antitrypsin Deficiency Adult Liver Study

NCT02014415
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Liver Biopsy (Biopsy Group Only)
Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 8:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Blood Collection for Development and Validation of Point-of-Care Diagnostic Liver Function Tests

NCT05457543
View directory record Official record
Conditions
Liver Diseases, Healthy, Liver Cirrhosis, Liver Fibrosis
Interventions
Adult
Diagnostic Test
Lead sponsor
Group K Diagnostics Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 22, 2026, 8:05 AM EDT
Active, not recruiting Not applicable Interventional

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT04820036
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interaction Between Cannabidiol, Meal Ingestion, and Liver Function

NCT04971837
View directory record Official record
Conditions
Metabolism, Liver Function, Pharmacokinetics
Interventions
Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation, Cannabidiol (CBD) Gum Arabic, sorbitol base formulation, Cannabidiol (CBD) Isolate in water formulation, CBD matching Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 22, 2026, 8:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

NCT07106879
View directory record Official record
Conditions
Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions
Blood Work
Other
Lead sponsor
Clindove Research LLC
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 22, 2026, 8:05 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

NCT03702218
View directory record Official record
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

NCT01638559
View directory record Official record
Conditions
Liver Transplant Recipients, Liver Transplantation, Immunosuppression
Interventions
Immunosuppression withdrawal
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 22, 2026, 8:05 AM EDT
Not listed No phase listed Observational

Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women

NCT03767803
View directory record Official record
Conditions
Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema, Headache, Visual Impairment
Interventions
Non-interventional study
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
San Diego, California • Newark, Delaware • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 22, 2026, 8:05 AM EDT
Terminated Phase 2 Interventional

Quantitative Liver Function Tests Using Cholates

NCT01907074
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Cholates
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 22, 2026, 8:05 AM EDT
Recruiting No phase listed Observational

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

NCT06225193
View directory record Official record
Conditions
Fatty Liver
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 8:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration

NCT02218866
View directory record Official record
Conditions
Peripheral Neuropathy, Obesity
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

NCT01579162
View directory record Official record
Conditions
Hepatitis C, Chronic, Non-Alcoholic Fatty Liver Disease
Interventions
Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 22, 2026, 8:05 AM EDT
Recruiting No phase listed Observational

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

NCT07060547
View directory record Official record
Conditions
Alcoholic Hepatitis, Alcohol-related Liver Disease
Interventions
HepQuant DuO Test
Device
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589
View directory record Official record
Conditions
HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 8:05 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

NCT01548651
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 8:05 AM EDT
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 22, 2026, 8:05 AM EDT
Completed Phase 2 Interventional

Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

NCT02556372
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
JKB-122
Drug
Lead sponsor
TaiwanJ Pharmaceuticals Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 22, 2026, 8:05 AM EDT